Fibrinogen concentrate as a treatment for postpartum haemorrhage-induced coagulopathy: A study protocol for a randomised multicentre controlled trial. The fibrinogen in haemorrhage of DELivery (FIDEL) trial

Anaesthesia Critical Care and Pain Medicine

Volumn 35, Issue 4, 2016, Pages 293-298

  Ducloy Bouthors, Anne Sophie ^a   Mignon, Alexandre ^b   Huissoud, Cyril ^c   Grouin, Jean Marie ^d   Mercier, Frédéric J ^e  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Institut Cochin   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Blood transfusion; Fibrinogen concentrate; Postpartum haemorrhage

Indexed keywords

FIBRINOGEN; FIBRINOGEN CONCENTRATE; PLACEBO; PROSTAGLANDIN; SULPROSTONE; UTEROTONIC AGENT; HEMOSTATIC AGENT; OXYTOCIC AGENT; OXYTOCIN; PROSTAGLANDIN E2;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOGENOLYSIS; HUMAN; HYPOFIBRINOGENEMIA; MAJOR CLINICAL STUDY; MATERNAL MORTALITY; MULTICENTER STUDY; POSTPARTUM HEMORRHAGE; POSTPARTUM HEMORRHAGE INDUCED COAGULOPATHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK FACTOR; VAGINAL DELIVERY; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD COAGULATION DISORDERS; CLINICAL TRIAL; OBSTETRIC DELIVERY; PATIENT SAFETY; PHYSIOLOGIC MONITORING; PREGNANCY; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD COAGULATION DISORDERS; DELIVERY, OBSTETRIC; DINOPROSTONE; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; HEMOSTATICS; HUMANS; MONITORING, PHYSIOLOGIC; OXYTOCICS; OXYTOCIN; PATIENT SAFETY; POSTPARTUM HEMORRHAGE; PREGNANCY; PROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84989943388     PISSN: None     EISSN: 23525568     Source Type: Journal    
DOI: 10.1016/j.accpm.2015.10.011     Document Type: Article

References (31)

1. [1] Hogan, M.C., Foreman, K.J., Naghavi, M., Ahn, S.Y., Wang, M., Makela, S.M., et al. Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 375 (2010), 1609–1623.
2. [2] Knight, M., Callaghan, W.M., Berg, C., Alexander, S., Bouvier-Colle, M.H., Ford, J.B., et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth, 9, 2009, 55.
3. [3] Charbit, B., Mandelbrot, L., Samain, E., Baron, G., Haddaoui, B., Keita, H., et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 5 (2007), 266–273.
4. [4] de Lloyd, L., Bovington, R., Kaye, A., Collis, R.E., Rayment, R., Sanders, J., et al. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth 20 (2011), 135–141.
5. [5] Gayat, E., Resche-Rigon, M., Morel, O., Rossignol, M., Mantz, J., Nicolas-Robin, A., et al. Predictive factors of advanced interventional procedures in a multicentre severe postpartum haemorrhage study. Intensive Care Med 37 (2011), 1816–1825.
6. [6] Wikkelso, A., Lunde, J., Johansen, M., Stensballe, J., Wetterslev, J., Moller, A.M., et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev, 8, 2013, Cd008864.
7. [7] Levy, J.H., Welsby, I., Goodnough, L.T., Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 54 (2014), 1389–1405 [quiz 1388].
8. [8] Grottke, O., Braunschweig, T., Henzler, D., Coburn, M., Tolba, R., Rossaint, R., Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury. Crit Care, 14, 2010, R62.
9. [9] Hellgren, M., Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 29 (2003), 125–130.
10. [10] Cortet, M., Deneux-Tharaux, C., Dupont, C., Colin, C., Rudigoz, R.C., Bouvier-Colle, M.H., et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth 108 (2012), 984–989.
11. [11] Huissoud, C., Carrabin, N., Audibert, F., Levrat, A., Massignon, D., Berland, M., et al. Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. BJOG 116 (2009), 1097–1102.
12. [12] Karlsson, O., Jeppsson, A., Hellgren, M., Major obstetric haemorrhage: monitoring with thromboelastography, laboratory analyses or both?. Int J Obstet Anesth 23 (2014), 10–17.
13. [13] Collins, P.W., Liiley, G., Bruynseels, D., Laurent, D.B., Cannings-John, R., Precious, E., et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood 124 (2014), 1727–1736.
14. [14] Aawar, N., Alikhan, R., Bruynseels, D., Cannings-John, R., Collis, R., Dick, J., et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomized controlled trial. Trials, 16, 2015, 169.
15. [15] Onwuemene, O., Green, D., Keith, L., Postpartum hemorrhage management in 2012: predicting the future. Int J Gynaecol Obstet 119 (2012), 3–5.
16. [16] Fenger-Eriksen, C., Christiansen, K., Laurie, J., Sorensen, B., Rea, C., Fibrinogen concentrate and cryoprecipitate but not fresh frozen plasma correct low fibrinogen concentrations following in vitro haemodilution. Thromb Res 131 (2013), e210–e213.
17. [17] Ahmed, S., Harrity, C., Johnson, S., Varadkar, S., McMorrow, S., Fanning, R., et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage – an observational study. Transfus Med 22 (2012), 344–349.
18. [18] Kikuchi, M., Itakura, A., Miki, A., Nishibayashi, M., Ikebushi, K., Ishihara, O., Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy. J Obstet Gynaecol Res 39 (2013), 770–776.
19. [19] Makino, S., Takeda, S., Kobayashi, T., Murakami, M., Kubo, T., Hata, T., et al. National survey of fibrinogen concentrate usage for post-partum hemorrhage in Japan: investigated by the Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res 41 (2015), 1155–1160.
20. [20] Mallaiah, S., Barclay, P., Harrod, I., Chevannes, C., Bhalla, A., Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia 70 (2015), 166–175, 10.1111/anae.12859.
21. [21] Wikkelso, A.J., Edwards, H.M., Afshari, A., Stensballe, J., Langhoff-Ross, J., Albrechtsen, C., et al. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth 114 (2015), 623–633.
22. [22] Goffinet, F., Mercier, F., Teyssier, V., Pierre, F., Dreyfus, M., Mignon, A., et al. Groupe de travail des RCP sur l'HPP [Postpartum haemorrhage: recommendations for clinical practice by the CNGOF (December 2004)]. Gynecol Obstet Fertil 33 (2005), 268–274.
23. [23] Goffinet, F., [Postpartum haemorrhage: methods used and topics discussed in the CNGOF Recommendations for clinical practice (December 2004)]. Gynecol Obstet Fertil 33 (2005), 266–267.
24. [24] Jacobsen, A.F., Skjeldestad, F.E., Sandset, P.M., Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium – a register-based case-control study. Am J Obstet Gynecol 198 (2008), 233.e1–233.e7.
25. [25] Chauleur, C., Cochery-Nouvellon, E., Mercier, E., Aya, G., Marès, P., Mismetti, P., et al. Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohort. Thromb Haemost 100 (2008), 773–779.
26. [26] Kozek-Langenecker, S.A., Afshari, A., Albaladejo, P., Santullano, C.A., De Robertis, E., Filipescu, D.C., et al. Management of severe postoperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 30 (2013), 270–382.
27. [27] Bonnet, M.P., Deneux-Tharaux, C., Bouvier-Colle, M.H., Critical care and transfusion management in maternal deaths from postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol 158 (2011), 183–188.
28. [28] Collis, R.E., Collins, P.W., Haemostatic management of obstetric haemorrhage. Anaesthesia 70:Suppl 1 (2015), 78–86.
29. [29] Summary of product characteristics (SmPC) clottafact (human fibrinogen) 1.5 g/100 mL powder and solvent for solution for injection. 2009, LFB-BIOMEDICAMENTS [Available from: http://www.has-ante.fr/portail/upload/docs/application/pdf/2009-07/clottafact_-_ct6697.pdf.C, 30-12-2014].
30. [30] Mercier, F.J., Van de Velde, M., Major obstetric hemorrhage. Anesthesiol Clin 26 (2008), 53–66.
31. [31] Ducloy-Bouthors, A.S., Susen, S., Wong, C.A., Butwick, A., Vallet, B., Lockhart, E., Medical advances in the treatment of postpartum hemorrhage. Anesth Analg 119 (2014), 1140–1147 [Erratum in: Anesth Analg 2015; 120: 494].